Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Females with 5 alpha-reductase-2 deficiency have less body hair, no acne, normal fertility, and delayed menarche.

Hormone treatments in transsexual individuals reduce hair growth and oil production in male-to-females and increase them in female-to-males.

The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.

Cyproterone acetate is a safe treatment that causes mild feminizing effects in adolescent trans-girls.

Male and female mice have different skin thickness, and hormones affect their skin and hair growth differently.

Polycystic Ovary Syndrome (PCOS) affects Iranian women's feelings of femininity and self-image.

Feminizing hormone therapy increases hair counts and improves hair-related quality of life, while masculinizing therapy may reduce large terminal hairs.

Transgender patients on hormone therapy experience more acne and hair loss, but less skin inflammation.

Gender-affirming hormone therapy may increase heart disease risk in transgender individuals.

Masculinization in affected individuals occurs gradually after puberty due to hormone changes.

Gender-affirming hormone therapy changes hair growth in transgender people, with feminizing therapy reducing hair and masculinizing therapy increasing it, but sometimes additional treatment is needed.

Male and female skin differ in many ways, which could lead to gender-specific skin treatments.

Gender-affirming hormone therapy in South Korea aligns with international guidelines and has specific side effects.

Understanding gender differences and individual patient characteristics is essential for optimal cosmetic surgery outcomes.

Exposure to low doses of finasteride in the womb causes changes in the prostate of both male and female gerbils.

Gender-affirming hormone therapy and surgery affect gut bacteria differently.

Progesterone may help trans women with breast development and health, but more research is needed.

Women generally handle heart enlargement better than men, but it's riskier for them if it occurs; hormones like estrogen offer some protection.

Finasteride and dutasteride are not recommended for feminizing therapy due to limited effectiveness and potential risks.

Gendered social factors, not just biology, contribute to sex differences in adverse drug events.

Prenatal pesticide exposure may cause earlier breast development in girls.

Blocking androgen receptors early in life increases estrogen levels and reduces sexual motivation in male rats.

5alpha-reductase 2 is crucial for proper male brain development and sexual differentiation.

Finasteride and dutasteride have limited use in feminising therapy and are not recommended for routine use.

Testosterone treatment effectively causes male physical development in transgender male adolescents but may lead to side effects like acne, higher BMI and blood pressure, lower good cholesterol, and decreased bone density.

Transgender women have similar fitness to cisgender women, while transgender men have higher fat and lower strength than cisgender men; hormone therapy affects body composition and strength.

Men and women react differently to opioids, with hormones potentially influencing these differences.

Gender-affirming hormone therapy affects health risks and requires careful management, especially as transgender individuals age.

High levels of male hormones in pregnant mice cause heart enlargement and poor heart function in their female babies.

African-American girls tend to start puberty earlier than white girls, possibly due to increased androgen production.